INTEC PARENT INC.
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | NTEC |
| ISIN: | IL0011177958 |
INTEC PARENT INC. news, videos and press releases
For more news please use our advanced search feature.
INTEC PARENT INC. - More news...
INTEC PARENT INC. - More news...
- 10/10/2024 - 12:00 Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
- 10/08/2024 - 12:00 Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
- 09/05/2024 - 12:30 Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
- 09/03/2024 - 12:00 Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- 08/12/2024 - 12:00 Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- 08/07/2024 - 11:00 Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
- 06/11/2024 - 12:00 Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit
- 06/04/2024 - 12:00 Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
- 06/03/2024 - 12:00 Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
- 05/30/2024 - 12:00 Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference
- 05/29/2024 - 12:00 Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
- 05/22/2024 - 12:00 Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
- 05/08/2024 - 12:00 Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- 04/11/2024 - 11:30 Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
- 03/28/2024 - 12:00 Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
- 03/25/2024 - 12:30 Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
- 03/18/2024 - 12:00 Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
- 03/13/2024 - 11:30 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- 03/04/2024 - 12:30 Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
- 02/15/2024 - 13:00 Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
- 02/08/2024 - 13:00 Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
- 01/04/2024 - 13:00 European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
- 11/06/2023 - 21:01 Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- 11/06/2023 - 13:00 Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
- 10/31/2023 - 13:01 Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
- 09/27/2023 - 12:00 Indaptus Therapeutics to Present at the LD Micro Main Event XVI
- 09/26/2023 - 12:00 Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023
- 09/19/2023 - 12:00 Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
- 09/06/2023 - 12:05 Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- 08/14/2023 - 12:00 Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
